A5022554263- Lymphoma Diagnosis and Treatment
- Complement system in diseases
- Acute Lymphoblastic Leukemia research
- Ovarian cancer diagnosis and treatment
- Chronic Lymphocytic Leukemia Research
- Endometrial and Cervical Cancer Treatments
- Blood disorders and treatments
- Hematopoietic Stem Cell Transplantation
- Blood transfusion and management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Renal Diseases and Glomerulopathies
- Cancer Genomics and Diagnostics
- Systemic Lupus Erythematosus Research
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
- Statistical Methods in Clinical Trials
- Esophageal Cancer Research and Treatment
- Transgenic Plants and Applications
- Gastrointestinal Tumor Research and Treatment
- Ethics and Legal Issues in Pediatric Healthcare
- CNS Lymphoma Diagnosis and Treatment
- Endometriosis Research and Treatment
- Immune Cell Function and Interaction
- Cerebrovascular and genetic disorders
Centre de Recherche en Informatique
2025
Université de Lille
2025
Hospital Universitario Son Espases
2013-2024
Health Research Institute of the Balearic Islands
2020-2024
Fundación Instituto Valenciano de Oncología
2014-2019
Immungenetics (Germany)
2017
Hospital Universitari i Politècnic La Fe
2015
Hospital Universitario Son Dureta
2007-2011
The aim of this study is to evaluate the diagnostic performance human epididymis protein 4 (HE4), cancer antigen 125 (Ca125) and risk ovarian malignancy algorithm (ROMA) in discriminating from other benign gynaecological diseases. Serum levels HE4 Ca125 were measured 119 women with diseases, 29 patients primary cancer, 32 on chemotherapy treatment (18 them progressive disease), 6 treated free disease healthy women. Sensitivity, specificity, positive negative predictive values likelihood...
DLBCL is an aggressive lymphoma treated with R-CHOP. Recently, attempts have been made to improve the outcome by increasing both dose-density and intensity but there no benefits in terms of survival. When treating malignancies RDI important consider little published information on DLBCL. The purpose this study was analyze differential prognostic impact two cohorts patients R-CHOP21 or R-CHOP14. From January 2001 August 2013 we included homogenously R-CHOP14, without radiotherapy, at...
Psoriasis is a chronic pathology characterized by increased inflammation that can be associated with changes in the vascular endothelium. We quantified levels of circulating endothelial cells (CECs) and microparticles (MPs) patients psoriasis order to analyze their relationship markers, subclinical atherosclerosis microcirculation.We studied 20 controls. Circulating markers damage (CEC, MPs von Willebrand factor, vWF) (E-selectin, E-sel; Interleukin-6, IL-6 C-reactive protein, CRP) were...
Thrombotic microangiopathy (TMA) is an important complication associated with several diseases that are rare and life-threatening. TMA common to thrombotic thrombocytopenic purpura (TTP) hemolytic uremic syndrome (HUS). TTP defined by a severe deficiency of ADAMTS13, early treatment good prognosis. The diagnosis HUS can be difficult due the potential multiple etiologies, best option in most cases not well-established yet. implementation multidisciplinary team (MDT) could decrease time for...
Central nervous system (CNS) lymphomatosis is a fatal complication of aggressive non-Hodgkin lymphoma (NHL). In lymphoblastic or Burkitt lymphoma, without specific CNS prophylaxis the risk relapse 20–30%. DLBCL has lower (around 5%) but several factors increase its incidence. There no consensus trials to conclude which best prophylaxis. Best results seem be associated with use intravenous (iv) high-dose methotrexate (HDMTX) significant toxicity. Other options are administration intrathecal...
Thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia, thrombocytopenia, and multisystem organ dysfunction, is a life-threatening disease. Patients with TMA who do not exhibit severe ADAMTS-13 deficiency (defined as disintegrin-like metalloprotease thrombospondin type 1 motif no. 13 activity ≥10%: TMA-13n) continue to experience elevated mortality rates. This study explores the prognostic indicators for augmented risk or necessitating chronic renal replacement...
e17116 Background: The characterization and prognostic relevance of immune cells in the tumor microenvironment endometrial cancer (EC) remain unknown. Our aims are to analyze presence infiltrating lymphocytes (TIL) peritumoral (PTL) tumoral tissue patients with EC, identify correlation between TILs PTLs subsets clinicopathologic features its value Methods: CD3, CD4, CD8, CD20, FOXP-3 was determined by immunohistochemestry (IHQ). A 4-point score defined based on TIL counts per highpowered...
patients with AAV.
e17061 Background: Ovarian carcinoma represents a heterogeneous group of disease. Clear cell (CCC), an infrequent subtype, presents particular clinical characteristics and genetic profiles. PIK3CA mutations (PIK3CAmut) in CCC represent the highest frequency among all cancer types potential target treatment. High microsatellite instability (MSI-H) is reported around 14%. Methods: From retrospective two-institutional database with cases ranging from 1997 to 2015, 24 ovarian CCCs were analyzed...
IntroductionRecently oral Busulfan (OBu) has been replaced by intravenous Bu (IVBu) in allogeneic stem cell transplantation (HCT) conditioning regimens acute leukaemia (AL) due more predictable pharmacokinetic and lower toxicity.Patients MethodsWe present results from a single centre, retrospective study, using IVBu vs OBu plus Fludarabine (Flu) or Cyclofosfamide (Cy) as reduced-intensity (RIC) myeloablative regimen AL patients.We analyzed 66 patients, 2000 to 2010, with median age 45 (8-71)...